Industrifonden

Unreasonable inventors are combining cutting edge scientific discoveries with the world's biggest challenges to build the next generation of global companies. These are the companies we create and invest in at Main Sequence. We have over $500m under management from lean-in LPs who help our portfolio to prosper. We are investing in the difficult to build companies others struggle to support. Our co-founder is Australia's $1.3b annual budget science agency - CSIRO We invest from seed to Series B, starting our journey as early as possible, driving advantage into our portfolio. Our Advantage Deep tech inventors need more. We have custom built Main Sequence to be ready to help you solve some of the world's greatest challenges with science. We are hands-on and have built a services offering to support founders alongside our capital. Our story Main Sequence was created by CSIRO to address the ‘valley of death’ between research and commercialisation. It solves the world’s greatest challenges by turning our scientific breakthroughs into the next century’s giants. Main Sequence’s origins within CSIRO reflect its commitment to amplifying connections between industry, research and infrastructure to accelerate deep technology development, and reinvesting economic returns from commercialisation back into science. CSIRO Innovation Funds 1 and 2 managed by Main Sequence, have invested in 39 companies since establishment in 2017. These companies have created over 1,200 jobs by working with partners in industry, CSIRO, and 22 Australian universities. The $240 million first CSIRO Innovation Fund , built on a cornerstone investment by government and CSIRO has completed its portfolio and invested in 27 companies since establishment in 2017. The second $300 million CSIRO Innovation Fund commenced investing mid-2021 and had already invested in 12 companies by the end of 2021. Following the Government’s announcement on 1 February 2022 of a reform agenda to accelerate commercialisation of research and collaboration with industry, including $150m support for CSIRO investment in future CSIRO Innovation Funds, Main Sequence welcomes the opportunity to continue to work closely with universities to commercialise Australian research and build Australian companies addressing global challenges. Each of our portfolio companies has some advantage delivered by either one of Australia's 43 universities or an industrial research organisation such as CSIRO. In some cases this exists before we invest, in others we facilitate it as part of the companies pathway to scale and impact.

We are in the midst of technological shifts at a pace faster than ever before. Calculus VC capitalizes on these shifts to deliver returns and impact. We invest in the Series A and Series B stages of startups in the below sectors: FUTURE OF COMPUTING AND AI Continued advancements in AI will demand new developments in hardware and software. New computing materials and interfaces may emerge. Computing power may be more distributed, and the world will be infinitely more connected. These and more, are our areas of interest: Intelligence beyond language: We expect AI to understand quantitative models and physical phenomenon just as well as it understands language. Large Quantitiative Models are a focus for us. New hardware, materials, and architectures: We expect that demand for computing power will grow exponentially. Quantum computing, as well as distributed computing are expected to grow. We expect advancements in computing materials beyond silicon. Immersive and neural interfaces: These interfaces already exist, we expect they will become more mainstream. Spatial computing, integrating the physical world with digital environments may be our future. COMPUTATIONAL LIFE SCIENCES AND HEALTHTECH Breakthroughs in biology, materials, sensors, and data science are converging to redefine healthcare. Precision and personalization will take center stage as AI enhances how we detect, monitor, and treat disease. Areas of interest include: AI-First Therapeutics and Discovery Platforms: ML-powered platforms designing drugs and biologics via simulation, predictive modeling, and data-rich experimentation. Infrastructure for Programmable Biology: Tools that make biology engineerable – lab automation, bioinformatics, 3D bioprinting, next-gen diagnostics and R&D devices. Continuous, Data-Driven and Personalized Care: Wearables, medical devices, and diagnostics to deliver patient-centric care. These models turn users into real-time data streams, enabling adaptive treatment and personalized interventions. ADVANCED INDUSTRIAL TECHNOLOGIES As we expand the frontiers of possibility, we expect industry to evolve with intelligence, autonomy and environmental sustainability at its core. Areas of focus include: AI and automation in industry: Intelligent machines will optimize production, reduce waste, and enable new workflows. From predictive maintenance to robotic manufacturing, automation will power the next industrial revolution. We support startups enabling this vision. Land, ocean, and space transport and communications: We are interested in advanced materials, robotics, sensors, systems and software that will unlock new frontiers from deep-sea mapping to planetary missions. Resource efficiency: Building the future will demand large reserves of energy and natural resources. Technologies that can serve our energy, food, water, and agricultural needs while supporting a better planet are of interest to us.

We use our domain expertise, network, and prior experiences to help our founders scale commercialization, product, and engineering. Post-science project investing We recognize that starting and building a company is hard. Startups by definition are outliers being built by unique collections of humans. We utilize our deep domain expertise to uniquely understand the problems of companies in the categories we care about. Pairing this with our experience working with deep technology, allows us to provide leverage in taking a company from pre, to post-commercialization and building engineering teams across both research and production-level eng.

We invest in early-stage R&D-focused individuals and teams solving complex technical challenges with large potential for commercial application. INVESTMENT AREAS We like to invest in teams building solutions in these technical domains: Software++AI & ML Big Data AR, VR & XR Cybersecurity Cloud/DevSecOps Distributed systems Performance computing Life SciencePersonalized medicine Drug discovery software Precision medicine Biofabrication Digital twins Organoids other BioTech, MedTech HardwareRobotics Automation IoT Industry 4.0 Nanotechnology Material Science Space

Oxygea is here to accelerate and invest in people and their business that will drive sustainable innovation and digital transformation. We value ecosystems and we cooperate with local and global networks to provide only the best to startups that will transform the future of the industry. Where do we invest? Circular Economy Technologies intended for reintegrating plastic waste to production chain Extend the useful lifecycle of plastic applications A reduction in the need for production, use, or disposal Carbon Neutrality Energy transition New materials from renewable sources Carbon market CO2 capture, storage and utilization for new chemicals Biotechnology/ Nanotechnology and New Materials New biological and biochemical routes to produce chemicals, plastics and materials Advanced Materials Digital technologies for accelerating R&D developments Plastic as sustainable solution Biopolymers Plastic applications with performance gain Additive manufacturing Smart Factory & Future Mobility Industry 4.0: Analytics, automation and advanced manufacturing technologies Logistics 4.0: Logistics efficiency and improved traceability

elev8.vc is a B2B focused VC Fund based in Singapore, with interests globally. We invest in and support early-stage deep tech founders (up to Series A), to scale their businesses globally.